Vivian F Go1, Constantine Frangakis, Nguyen Le Minh, Tran Viet Ha, Carl A Latkin, Teerada Sripaipan, Carla E Zelaya, Wendy W Davis, David D Celentano, Vu Minh Quan. 1. *Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC; †Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; ‡Centre for Preventive Medicine of Thai Nguyen, Thai Nguyen, Vietnam; §University of North Carolina, UNC-Project Vietnam, Hanoi, Vietnam; ‖Department of Health, Behavior, and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; and ¶Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Abstract
OBJECTIVE: In Vietnam, where 58% of prevalent HIV cases are attributed to people who inject drugs, we evaluated whether a multi-level intervention could improve care outcomes and increase survival. METHODS: We enrolled 455 HIV-infected males who inject drugs from 32 communes in Thai Nguyen Province. Communes were randomized to a community stigma reduction intervention or standard of care and then within each commune, to an individual enhanced counseling intervention or standard of care, resulting into 4 arms: Arm 1 (standard of care); Arm 2 (community intervention alone); Arm 3 (individual intervention alone); and Arm 4 (community + individual interventions). Follow-up was conducted at 6, 12, 18, and 24 months to assess survival. RESULTS:Overall mortality was 23% (n = 103/455) more than 2 years. There were no losses to follow-up for the mortality endpoint. Survival at 24 months was different across arms: Arm 4 (87%) vs Arm 1 (82%) vs Arm 2 (68%) vs Arm 3 (73%); log-rank test for comparison among arms: P = 0.001. Among those with CD4 cell count <200 cells/mm and not on antiretroviral therapy at baseline (n = 162), survival at 24 months was higher in Arm 4 (84%) compared with other arms (Arm 1: 61%; Arm 2: 50%; Arm 3: 53%; P-value = 0.002). Overall, Arm 4 (community + individual interventions) had increased uptake of antiretroviral therapy compared with Arms 1, 2, and 3. CONCLUSIONS: This multi-level behavioral intervention seemed to increase survival of HIV-infected participants more than a 2-year period. Relative to the standard of care, the greatest intervention effect was among those with lower CD4 cell counts.
RCT Entities:
OBJECTIVE: In Vietnam, where 58% of prevalent HIV cases are attributed to people who inject drugs, we evaluated whether a multi-level intervention could improve care outcomes and increase survival. METHODS: We enrolled 455 HIV-infected males who inject drugs from 32 communes in Thai Nguyen Province. Communes were randomized to a community stigma reduction intervention or standard of care and then within each commune, to an individual enhanced counseling intervention or standard of care, resulting into 4 arms: Arm 1 (standard of care); Arm 2 (community intervention alone); Arm 3 (individual intervention alone); and Arm 4 (community + individual interventions). Follow-up was conducted at 6, 12, 18, and 24 months to assess survival. RESULTS: Overall mortality was 23% (n = 103/455) more than 2 years. There were no losses to follow-up for the mortality endpoint. Survival at 24 months was different across arms: Arm 4 (87%) vs Arm 1 (82%) vs Arm 2 (68%) vs Arm 3 (73%); log-rank test for comparison among arms: P = 0.001. Among those with CD4 cell count <200 cells/mm and not on antiretroviral therapy at baseline (n = 162), survival at 24 months was higher in Arm 4 (84%) compared with other arms (Arm 1: 61%; Arm 2: 50%; Arm 3: 53%; P-value = 0.002). Overall, Arm 4 (community + individual interventions) had increased uptake of antiretroviral therapy compared with Arms 1, 2, and 3. CONCLUSIONS: This multi-level behavioral intervention seemed to increase survival of HIV-infectedparticipants more than a 2-year period. Relative to the standard of care, the greatest intervention effect was among those with lower CD4 cell counts.
Authors: S Koblavi-Dème; C Maurice; D Yavo; T S Sibailly; K N'guessan; Y Kamelan-Tano; S Z Wiktor; T H Roels; T Chorba; J N Nkengasong Journal: J Clin Microbiol Date: 2001-05 Impact factor: 5.948
Authors: Scott M Hammer; Joseph J Eron; Peter Reiss; Robert T Schooley; Melanie A Thompson; Sharon Walmsley; Pedro Cahn; Margaret A Fischl; Jose M Gatell; Martin S Hirsch; Donna M Jacobsen; Julio S G Montaner; Douglas D Richman; Patrick G Yeni; Paul A Volberding Journal: JAMA Date: 2008-08-06 Impact factor: 56.272
Authors: Vivian F Go; Constantine Frangakis; Nguyen Le Minh; Carl Latkin; Tran Viet Ha; Tran Thi Mo; Teerada Sripaipan; Wendy W Davis; Carla Zelaya; Pham The Vu; David D Celentano; Vu Minh Quan Journal: PLoS One Date: 2015-05-26 Impact factor: 3.240
Authors: Jonathan A C Sterne; Margaret May; Dominique Costagliola; Frank de Wolf; Andrew N Phillips; Ross Harris; Michele Jönsson Funk; Ronald B Geskus; John Gill; François Dabis; Jose M Miró; Amy C Justice; Bruno Ledergerber; Gerd Fätkenheuer; Robert S Hogg; Antonella D'Arminio Monforte; Michael Saag; Colette Smith; Schlomo Staszewski; Matthias Egger; Stephen R Cole Journal: Lancet Date: 2009-04-08 Impact factor: 79.321
Authors: Deepa Rao; Christopher G Kemp; David Huh; Paul E Nevin; Janet Turan; Susan E Cohn; Jane M Simoni; Michele Andrasik; Yamile Molina; Michael J Mugavero; Audrey L French Journal: J Acquir Immune Defic Syndr Date: 2018-07-01 Impact factor: 3.731
Authors: Sara N Levintow; Brian W Pence; Tran Viet Ha; Nguyen Le Minh; Teerada Sripaipan; Carl A Latkin; Pham The Vu; Vu Minh Quan; Constantine Frangakis; Vivian F Go Journal: AIDS Behav Date: 2019-03
Authors: M X Nguyen; D Dowdy; C A Latkin; H E Hutton; G Chander; C Frangakis; K E Lancaster; T Sripaipan; Q X Bui; H V Tran; V F Go Journal: Drug Alcohol Depend Date: 2020-08-25 Impact factor: 4.492
Authors: Rebecca B Hershow; Nisha C Gottfredson; Tran Viet Ha; Viet Anh Chu; Kathryn E Lancaster; Vu M Quan; Sara N Levintow; Teerada Sripaipan; Bradley N Gaynes; Brian W Pence; Vivian F Go Journal: Subst Use Misuse Date: 2020-04-08 Impact factor: 2.164
Authors: Kathryn E Lancaster; Angela Hetrick; Teerada Sripaipan; Tran Viet Ha; Heidi E Hutton; Geetanjali Chander; Carl A Latkin; David Dowdy; Constantine Frangakis; Bui Xuan Quynh; Vivian F Go Journal: PLoS One Date: 2020-09-30 Impact factor: 3.240
Authors: William C Miller; Irving F Hoffman; Brett S Hanscom; Tran V Ha; Kostyantyn Dumchev; Zubairi Djoerban; Scott M Rose; Carl A Latkin; David S Metzger; Kathryn E Lancaster; Vivian F Go; Sergii Dvoriak; Katie R Mollan; Sarah A Reifeis; Estelle M Piwowar-Manning; Paul Richardson; Michael G Hudgens; Erica L Hamilton; Jeremy Sugarman; Susan H Eshleman; Hepa Susami; Viet Anh Chu; Samsuridjal Djauzi; Tetiana Kiriazova; Duong D Bui; Steffanie A Strathdee; David N Burns Journal: Lancet Date: 2018-09-01 Impact factor: 202.731